Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 36fludarabine phosphate 32Tacrolimus 28Busulfan 24Peripheral Blood Stem Cell Transplantation 23Mycophenolic Acid 20Whole-Body Irradiation 19Antilymphocyte Serum 18Methotrexate 16fludarabine 14ruxolitinib 13Melphalan 12Cyclosporine 12thymoglobulin 8Stem Cell Transplantation 8Radiotherapy 8Methylprednisolone 8Sirolimus 6Prednisone 6Cord Blood Stem Cell Transplantation 6Specimen Handling 5Filgrastim 5Etoposide 5Alemtuzumab 5merphos 4itacitinib 4Imatinib Mesylate 4INCB039110 4Hematopoietic Stem Cell Transplantation 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Primary Myelofibrosis × lorvotuzumab mertansine × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡